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Exhaled nitric oxide (eNO) detects airway inflammation. Hyperbaric oxygen therapy (HBOT) is used for tissue hypoxia, but can
cause lung damage. We measured eNO following inhalation of oxygen at different tensions and pressures. Methods. Part 1, eNO
was measured before and after HBOT. Part 2, normal subjects breathed 40% oxygen. Results. Baseline eNO levels in patients prior
to HBOT exposure were significantly higher than in normal subjects (P < .05). After HBOT, eNO significantly decreased in patients
(15.4 ± 2.0 versus 4.4 ± 0.5 ppb, P < .001), but not in normal subjects, after either 100% O2 at increased pressure or 40% oxygen,
1 ATA. In an in vitro study, nitrate/nitrite release decreased after 90 minutes HBOT in airway epithelial (A549) cells. Conclusion.
HBO exposure causes a fall in eNO. Inducible nitric oxide synthase (iNOS) may cause elevated eNO in patients secondary to
inflammation, and inhibition of iNOS may be the mechanism of the reduction of eNO seen with HBOT.
Copyright © 2006 Zudin A. Puthucheary et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Exhaled nitric oxide (eNO) is a marker of airway inflamma-
tion [1]. Although NO is produced in the airways by a va-
riety of cells, large amounts may be generated from those
involved in the acute and chronic inflammatory responses
[2]. NO plays a role in pulmonary host defence mechanisms,
and is thought to have both bactericidal and bacteriostatic ef-
fects [3, 4]. Exhaled NO is released by nitric oxide synthases
(NOS), including neuronal NOS (nNOS, Type 1), inducible
NOS (iNOS, Type 2), and endothelial NOS (ecNOS, Type 3).
These NOS isoforms have been demonstrated in the airways
of many mammalian species including man [5, 6]. iNOS is
generally not expressed unless the cells have been induced by
certain cytokines, however, when stimulated, high concen-
trations (μM) of NO are produced [7–9]. Thus, an increase
in exhaled NO may be due to upregulation of iNOS within
epithelial cells in response to proinflammatory cytokines and
oxidants [10, 11].
In recent years, eNO has been used as a sensitive marker
of asthmatic airway inflammation [12, 13]. The assay is easy
to perform and reproducible with clinically useful sensitivity
and specificity [1].
Hyperbaric oxygen therapy (HBOT) is used for the treat-
ment of a number of conditions associated with tissue hy-
poxia, including late radiation tissue injury and diabetic
foot ulcers. These conditions are associated with hypoxia
at the site of disease, and improving oxygenation may as-
sist in the resolution of these lesions. Despite these ben-
eficial effects, HBOT is associated with some undesirable
side effects. Hyperoxia has long been associated with tis-
sue damage and the development of lung diseases. The
mechanism is not fully understood, but may be attributed
to reactive oxygen species (producing oxygen free radicals,
ROS) which induce the pulmonary cytochrome P450 en-
zymes [14–16]. This is supported by animal research into
neonatal bronchopulmonary dysplasia, which has shown
an arrest in alveolar and capillary development in posi-
tive pressure ventilated animals [17]. It has been reported
that ventilation with atmospheric hyperoxia in isolated per-
fused lungs increased NO generation [18, 19]. Conflicting
reports in the literature have been described in studies of
humans breathing 100% O2 [20, 21]. These changes asso-
ciated with hyperoxia have been explained by the bonding
of oxygen free radicals (O·) to extracellular NO in the body
generating peroxynitrite (ONOO−) which is a strong ox-
idant and which has been reported to increase iNOS ex-
pression [22–25]. However, not all studies are consistent
with these findings and hyperbaric oxygenation (HBO) has
been shown to decrease NO generation in animal models
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of shock, perhaps via a decrease in the activity of iNOS
[26].
This study aimed to measure alterations in eNO follow-
ing a standard hyperbaric oxygen regime in those with tis-
sue hypoxia and to compare them with normal subjects who
were either attendants in the HBO chamber or who breathed
supplemental oxygen at sea level. It was hypothesised that hy-
peroxia could downregulate exhaled nitric oxide. In addition
it was hypothesised that the changes in eNO would be re-
flected in the ability of isolated pulmonary cells to generate




Following the ethics committee’s approval of the experimen-
tal protocol and written informed consent, patients under-
going HBO at the Prince of Wales Hospital Department of
Diving and Hyperbaric Medicine were recruited to the study.
All patients were undergoing HBOT for medical indications
and no patient was subjected to HBOT purely for the sake
of the study. These subjects were asked to complete a ques-
tionnaire detailing their medical history, current medications
(particularly the use of glucocorticosteroids or nonsteroidal
anti-inflammatory agents (NSAIDS)), and specific questions
regarding the diagnoses of asthma, chronic obstructive pul-
monary disease or other pulmonary diseases, diabetes mel-
litus, and ischemic heart disease. Smoking history was ob-
tained. Normal subjects were recruited from hospital staff
and also completed the same questionnaire.
Exhaled nitric oxide measurements
The sampling and measurement procedure was as follows:
subjects were asked to inhale orally and exhale into a 2-liter
gas impermeable bag with a one way valve, generating a pos-
itive pressure to close the velum [27, 28]. If unable to fill this
in one breath, a second breath was used. The samples were
then analysed within 60 minutes using a closed gas circuit
connected to a chemiluminescent nitric oxide analyser, (Da-
sibi Environmental Corp, Glendale, Calif, USA) for NO and
Spacelabs Capnograph Model 90513-30 (Redmond, Wash,
USA) for CO2. The values obtained are therefore an average




All patients and attendants provided an expired NO sample
prior to compression, the patients then underwent a stan-
dard 90-minute HBOT session at 2.4 atmospheres absolute
(ATA), breathing 100% O2. These sessions involve a five
to ten minute compression phase breathing air, 90 minutes
breathing 100% oxygen at 2.4 ATA by demand valve mask or
hood, and a further 20 minutes slow decompression while
continuing to breathe oxygen. The total time in the cham-
ber for each session is therefore approximately two hours.
During this period they were accompanied by a trained hy-
perbaric chamber nursing attendant who breathed air dur-
ing the compression and 2.4 ATA periods, before starting
100% oxygen for the 20-minute decompression phase. This
is a standard operating procedure to reduce the risk of de-
compression illness for the attendant. For our experimen-
tal protocol, the attendants supplied a further sample of ex-
pired gas at 2.4 ATA before starting their oxygen breathing
period.
Immediately on exiting the hyperbaric chamber, a fur-
ther exhaled NO sample was taken from patients and staff.
Part two
A separate section studied normal subjects breathing 40%
oxygen for 90 minutes via a face mask at 1 ATA. Exhaled NO
samples were collected every 15 minutes.
Part three
A549 cells, an immortalised cell line derived from a lung ep-
ithelial cell carcinoma, were used as a model of airway ep-
ithelium. These cells have been demonstrated to be able to
express iNOS and to be able to generate nitrite [29]. Four
plates of 2 − 4 × 106 A549 cells were incubated in F12-K
media with 10% foetal calf serum (FCS) and exposed to
the following conditions for 90 min: (a) room temperature
and ambient air (plate A); (b) 100% oxygen at normal pres-
sure (plate B); (c) air at 2.4 ATA pressure (plate C); and
(d) 100% oxygen at 2.4 ATA (plate D). Interferon gamma
is known to stimulate A549 cells to increase NO produc-
tion [30]. Under each of the conditions, A549 cells were
therefore cultured in media with 0, 10, and 20 ng/mL re-
combinant human interferon gamma (hIFN γ, Serotec Ltd,
UK). Nitrite/nitrate (NOx) was measured by using a fluores-
cent method [31]. Samples were mixed with NADPH, FAD
(Sigma, Sydney, Australia), and nitrate reductase with a fi-
nal concentration of 50 μM, 5 μM, and 50 IU/L, respectively,
and incubated in 37◦C for 1 h, which allows nitrate to be
converted to nitrite. Nitrite was conjugated with 0.05 mg/mL
2,3-diaminonaphthalene (DAN) in 0.62 M HCL to allow
quantification by fluorescence. The reaction was terminated
with 2.8 M NaOH. The resultant fluorescence was immedi-
ately read on a CytoFluro Series 4000, Multiwell Plate Reader
(Perseptive Biosystems, Mass, USA) at excitation 360/40,
emission 395/25, gain 50, limit of detection 2 μmol/L, mean
(SD) intra-assay coefficient of variation 3.11(3.42)%. Data
are expressed as % change from baseline.
Analysis
Data are presented as mean ± SE. The results were analysed
using changes in NO (ppb) and CO2 (mmHg), after the NO
values were log transformed to the normal distribution [13].
Student’s t test was used to calculate P-values, which were
considered significant if P < .05.
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Foot ulcers 6 0
Osteoradionecrosis 7 0
Dental caries 1 0
Radiation cystitis 1 0






















Figure 1: Exhaled nitric oxide levels in 15 patients undergoing
HBOT immediately before and after treatment. There was a sig-
nificant fall in these patients (mean ± SE, before 15.4 ± 2.0 ppb,
afterwards 4.4± 0.5 ppb, P < .001).
RESULTS
Part one
In total, 16 attendants and 15 patients were recruited. Of the
patients, 12 were not on current glucocorticosteroid therapy
and 10 were not current steroid or NSAID users (Table 1).
One attendant omitted to collect a breath sample in the
chamber and other two samples collected in the chamber
were lost due to overexpansion and ultimate failure of the gas
collection bag during decompression. Mean (SD) coefficient
of variation of interbag exhaled NO levels was 6.36(1.17)%.
The initial mean eNO level in patients was significantly
higher than both that in attendants (15.4 ± 2.0 ppb vs 7.6 ±
1.1 ppb, P < .05) and the normal subjects in Part 2 (5.3 ±
1.0 ppb, P < .01). No difference in the initial exhaled NO
level was found between the attendants and normal subjects
at 1 ATA (7.6± 1.1 ppb vs 5.3± 1.0 ppb, resp, P = .14).
Patients
eNO significantly decreased after HBOT (Figure 1, 15.4±2.0
vs 4.4 ± 0.5 ppb, P < .001, n = 15). This effect was present
in both the subgroup not on glucocorticosteroids (15.2± 2.3



















Figure 2: Exhaled nitric oxide levels in 16 normal staff members
who were exposed to the hyperbaric environment but did not use
oxygen until immediately prior to decompression. There were no
significant changes between the samples.
vs 4.3 ± 0.6 ppb, P < .001, n = 12) and in the subgroup
on neither glucocorticosteroids nor NSAIDs (16.1 ± 2.5 vs
4.4 ± 0.6 ppb, P < .001, n = 10). Exhaled CO2 showed a
small but significant increase following HBOT in the patient
group (25.5 mmHg± 1.0 vs 27.3 mmHg± 0.9, P < .05).
Attendants in the hyperbaric chamber
The mean exhaled NO level before hyperbaric exposure was
7.6± 1.1 ppb and the mean level was 7.9± 0.9 ppb (Figure 2,
P = .46, n = 16) afterwards.
Part two
Normal subjects breathing 40% oxygen at 1 ATA
Mean exhaled NO levels in this normal group of subjects
were 5.3± 1.0 ppb before and 4.6± 1.1 after 90-minute 40%
oxygen inhalation (P = .22, n = 8), with no significant
change in exhaled NO levels at any of the 15-minute inter-
vals.
Part three
There was a significant decrease in NOx release into the cell
culture media after exposure to 100% oxygen for 90 minutes
in the A549 cells incubated in media alone (32.49% change
from baseline vs 9.38%, P < .01) and media with 20 ng/mL
hIFN γ (33.58% vs 9.25%, P < .05). The hyperbaric en-
vironment alone did not cause significant changes (32.49%
vs 22.80%, P = .32 in media only, and 33.58% vs 20.64%,
P = .29 in media with 20 ng/mL hIFN γ).
DISCUSSION
In this study, eNO levels of patients were significantly de-
creased after HBOT. In normal subjects eNO did not de-
crease significantly after either a short exposure to 100% oxy-
gen during decompression, or 40% oxygen for 90 minutes
in normal subjects. The decrease in eNO seen in the HBOT
patient group has been observed in studies using oxygen at
1 ATA. For example, Tsuchiya demonstrated inhalation of
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100% oxygen for 50 minutes reduced exhaled NO levels while
inhalation of 40% oxygen in a second group of mechani-
cally ventilated human subjects undergoing surgery did not
[21]. It is possible, however, that endogenous NO might be
affected by anaesthetic agents, surgery, the increased airway
pressure during mechanical ventilation, and these individu-
als may not show the same response as spontaneously breath-
ing individuals. It is worth noting that both our study and
that of Tsuchiya showed that 40% oxygen inhalation did not
change eNO levels significantly [21]. The 40% oxygen inhala-
tion was chosen as it allowed a conventional mask to be used,
but it would have been a more accurate comparison of the
equivalent 2.4 ATA exposure if 50.4% oxygen had been used.
In Part 1 of this study, no significant changes in eNO lev-
els were observed in normal subjects after breathing hyper-
baric air at 2.4 ATA for 90 minutes. This exposure is equiv-
alent to breathing 50.4% oxygen at 1 ATA (the inspired pO2
is approximately 361 mmHg in each case). Compared with
the hyperbaric oxygen at the same pressure inhaled by the
patients, it could be concluded that pressure is not the main
factor altering the eNO levels in this study, although these
normal subjects had a lower baseline eNO.
The increase in exhaled CO2 in the patients is presum-
ably due to either stimulation of NADPH turnover through
the pentose cycle or, more likely, suppression of their hypoxic
ventilatory drive [32–34].
The attendants received less hyperbaric oxygen exposure
than the patients and we acknowledge this may bias the re-
sult towards no change in these individuals. In addition, this
group was younger and generally more physically fit. The lack
of inflammatory diseases in both control groups probably ac-
counts for the difference in baseline eNO between them and
the patients. Half of the patients had osteoradionecrosis of
the head and neck, initial mean exhaled NO 15.0± 2.88 ppb,
which may be associated with inflammation of the upper air-
way. Those without osteoradionecrosis, however, had a sim-
ilar baseline exhaled NO. The reason for this is unclear but
may be related to inflammation associated with their under-
lying condition with foot ulcers being the most common in-
dication for HBOT. These conditions were associated with
an elevated eNO above our normal range [35]. Although
this was a prospective study, patients were recruited at var-
ious times during their HBOT, which may have influenced
the baseline exhaled NO values. It was hypothesised that
the elevated baseline exhaled NO in the patients was related
to the induction of iNOS. Inducible NOS is generally not
expressed unless the cells have been activated by inflamma-
tory cytokines [7–9, 36, 37].
Inhibition of iNOS in patients by HBOT may account for
the decrease of eNO levels. Recent studies have demonstrated
that oxidative stress also prevented iNOS induction in intesti-
nal epithelial cells [38, 39]. Yuan et al showed that hyperbaric
oxygen (HBO) suppressed iNOS expression in rabbit chon-
drocytes, and Pedoto et al reported that HBO decreased ex-
haled NO generation, plasma nitrite/nitrate concentration,
and iNOS expression in the rat lung [26, 38, 40]. Absent or
low levels of iNOS in normal subjects could explain why eNO
levels did not change after oxygen inhalation.
Changes in production of ROS or inhibition of iNOS ex-
pression would be two possible reasons for the decrease in
eNO after inhalation of high concentrations of oxygen for
a long period although no study has addressed the effect of
short exposure to HBOT in terms of oxidative status [41].
ROS generally increase inflammation, which would be ex-
pected to increase iNOS expression. It is possible, however,
that ROS could react with NO, and convert it to other NOx
species. This seems unlikely as the in vitro studies showed a
decline in NOx with O2 exposure.
It has been reported that a combination of interferon
gamma and interleukin 4 stimulates and maintains iNOS
expression in human airway epithelium [42]. This study
showed that NOx released from the A549 cell line incubated
in media alone or with 20 ng/mL human interferon gamma
significantly decreased after exposure to 100% oxygen, which
occurred in the absence of HBO. This suggests that inhibition
of iNOS may be the mechanism of the reduction in eNO seen
in patients. It has been demonstrated that iNOS is expressed
under resting conditions in the A549 cell line, which could
explain the decrease in NOx release after 100% oxygen expo-
sure in the A549 cell line incubated in media only [29].
In conclusion, our results suggest that inhibition of iNOS
may be the mechanism of HBOT-induced reduction in eNO.
This might have beneficial effects on inflammation, a ques-
tion which could to be further investigated by measurement
of iNOS expression in a randomized controlled study in re-
sponse to hyperoxia.
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